Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANKU-Breast03: BL-B01D1 versus physician's choice chemotherapy in endocrine-resistant HR-positive/HER2-negative advanced breast cancer
CTR20262305Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in breast cancer, sponsored by Biokin Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20262305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262305.